Grail: A Cancer Test & A Run for the Money!

by

Alright, settle in, folks. We’re talking about Grail (GRAL +13.01%), a company trying to detect cancer early. And let me tell you, in the stock market, “early” is always good. Today, their stock jumped more than 13%. That’s not a bad day at the office. Not bad at all. It’s like finding a winning lottery ticket… except instead of a trip to Barbados, you’re funding potentially life-saving research. A slightly more responsible vacation, if you ask me.

Why Investors Are Suddenly All Over This Thing

So, what’s got everyone so excited? Well, Grail’s Galleri test – it’s been on the market four years now. Four years! That’s like, a century in biotech time. They’re actually selling this thing. Imagine that! They’re reporting 2025 revenue between $147 and $148 million, with Galleri contributing a hefty $136 to $137 million. That’s a lot of tests. A lot. It’s enough to make a venture capitalist weep… tears of joy, naturally.

Loading widget...

Now, let’s talk 2026. Management is predicting Galleri revenue will grow 22% to 32%. That’s a robust increase, folks. A very robust increase. And they’re getting a handle on the cash burn, too. Down to $274 million from $579 million last year. They’ve got $904 million in the bank, thanks to some savvy private placements and a nice $110 million investment from Samsung. That’s a serious pile of cash. They claim it’ll keep them afloat until 2030. 2030! That’s… well, that’s a long time in the stock market. We’ll see if they can navigate the asteroid field of quarterly reports and analyst downgrades.

The Big Kahuna: FDA Approval

But here’s the real kicker. They’re submitting their application for FDA approval in the first quarter. FDA approval, my friends, is the golden ticket. It opens the floodgates. Medical and insurance coverage, marketing campaigns… it’s a beautiful thing. It’s like turning on the tap and watching the money flow. (Don’t worry, it’s ethically sourced money… mostly.)

The application will be backed by data from trials in the U.S. and a massive 140,000-person trial in the U.K. with the National Health Service. The U.K. is a tough crowd, let me tell you. They’ve seen everything. But if they sign off on this test, that’s a game changer. So, there’s a lot to look forward to for Grail investors in 2026. There are, of course, risks. FDA approvals are never guaranteed. But for enterprising investors – the ones who aren’t afraid to roll the dice – this stock is… well, let’s just say it’s worth a look. Just don’t blame me if it crashes and burns. I’m just a humble observer… and a connoisseur of fine financial disasters.

Read More

2026-01-22 23:14